{"denoms":[{"counts":[{"groupId":"BG000","value":"59"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"98"}],"units":"Participants"}],"groups":[{"description":"Treatment-naïve participants with BRAF V600E-mutant metastatic NSCLC were enrolled to receive encorafenib 450 mg QD and binimetinib 45 mg BID in 28-day (±3 days) cycles and continued until the participants met the protocol-defined criteria for treatment withdrawal.","id":"BG000","title":"Treatment-Naive"},{"description":"Patients who had received 1) first-line treatment with standard platinum-based chemotherapy, or 2) first-line treatment with an anti-PD-1/PD-L1 inhibitor given alone, or in combination with platinum-based chemotherapy, or in combination with immunotherapy (eg, ipilimumab) with or without platinum-based chemotherapy were enrolled to receive encorafenib 450 mg QD and binimetinib 45 mg BID was to be administered in 28-day (±3 days) cycles and continued until the participants met the protocol-defined criteria for treatment withdrawal.","id":"BG001","title":"Previously Treated"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"47","upperLimit":"83","value":"68"},{"groupId":"BG001","lowerLimit":"53","upperLimit":"86","value":"71"},{"groupId":"BG002","lowerLimit":"47","upperLimit":"86","value":"69.5"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"33"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"52"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"46"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"7"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"53"},{"groupId":"BG001","value":"33"},{"groupId":"BG002","value":"86"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"7"},{"groupId":"BG002","value":"26"}]}],"title":"Grade 0"},{"categories":[{"measurements":[{"groupId":"BG000","value":"40"},{"groupId":"BG001","value":"32"},{"groupId":"BG002","value":"72"}]}],"title":"Grade 1"}],"description":"ECOG Performance Status Scoring: Grade 0: Fully active, able to carry on all predisease performance without restriction; Grade 1: restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature; Grade 2: ambulatory and capable of all self-care but unable to carry out any work activities; up and about more than 50% of waking hours; Grade 3: capable of only limited self-care; confined to bed or chair more than 50% of waking hours; Grade 4: Completely disabled; cannot carry on any self-care; totally confined to bed or chair; Grade 5: dead.","paramType":"COUNT_OF_PARTICIPANTS","title":"Eastern Cooperation Oncology Group (ECOG) Performance Status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"13"}]}],"title":"Current Smoking"},{"categories":[{"measurements":[{"groupId":"BG000","value":"33"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"56"}]}],"title":"Former Smoking"},{"categories":[{"measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"29"}]}],"title":"Never Smoking"}],"description":"Smoking history was collected at Screening by the Investigator or qualified designee.","paramType":"COUNT_OF_PARTICIPANTS","title":"Smoking Status","unitOfMeasure":"Participants"}],"populationDescription":"Baseline analysis population included all participants taking at least 1 dose of study intervention."}